Collectively, these data reinforce the anti-inflammatory role of tumor-intrinsic PPARγ/RXRα activity and potentially as a driver of resistance to immune checkpoint inhibitor therapies in bladder cancer. This evidence concerns the gene PPARG and urinary bladder carcinoma.